Cantor Fitzgerald Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating
Scotiabank Initiates Coverage On Aclaris Therapeutics With Sector Outperform Rating, Announces Price Target of $15
Aclaris Therapeutics Analyst Ratings
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Cuts Target Price to $2
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating, Announces Target Price $20
Jefferies Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
Aclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $5
Stifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)
Cantor Fitzgerald Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)